Calithera Biosciences, Inc.

The biopharmaceutical industry still has a long way to go to recover from valuation declines that began in 2021, but signs of improving health in the sector in late 2022 and unchanged business fundame

The sun shined on the first and last days of the J.P. Morgan Healthcare Conference, held 9-12 January in San Francisco, and the rain, winds and downed trees that soaked and blocked the paths of the me

Despite the announcement of three significant M&A deals on the first day of this year’s J.P. Morgan Healthcare Conference, the boost to health care stocks that often accompanies the meeting has not ye

Calithera Biosciences, Inc. has terminated development of its lead asset, telaglenastat, based on interim Phase II study data in lung cancer, forcing the company to re-shift its focus to two recently